Anticancer agent 114, a dipeptide boronic acid ester, functions as a potent proteasome inhibitor with an oral activity and demonstrates an IC50 of 2.2 nM. It exhibits antiproliferative properties specifically targeting RPMI-8226 cells, making it valuable for research into multiple myeloma [1].